Research area overview

Nanomedicines represent the next generation of advanced therapeutics. These can be designed to carry the drug specifically to target disease site (cell or tissue) so that unnecessary exposure of healthy tissue to the drug is minimised and drug side effects are reduced. They also offer significant potential in enabling oral administration of drugs currently requiring injections (e.g. insulin). Nanomedicine therefore offers advantages in terms of drug safety, efficacy and patient convenience.

Our nanomedicine research centres around the use of nanosystems

to enable mucosal (non-invasive) delivery of therapeutics that

currently require injections. 

As part of this research, we are also interested in the study of the

behaviour of drug delivery nanosystems at the interface with the

mucosal surfaces and within the complex environments of the

gastrointestinal system and the lungs. 

 

Current projects 

- 'Exosomes for non-invasive (mucosal) delivery of siRNA in Inflammatory Bowel Disease'

Select relevant publications

  1. Capel V, et al. Insight into the relationship between the cell culture model, cell trafficking and siRNA silencing efficiency. Biochem Biophys Res Commun 2016, 477 (2):260-265.

  2. Byrne G, Vllasaliu D et al. Live imaging of cellular internalization of single colloidal particle by combined label-free and fluorescence Total Internal Reflection Microscopy. Mol Pharm 2015, 12, (11):3862-70.

  3. Bannunah A, Vllasaliu D et al. Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. Mol Pharm 2014, 11, (12):4363-73.

  4. Vllasaliu D and Singh I. Particle characterisation in drug delivery. European Pharmaceutical Review 09/2014.

  5. Vllasaliu D, et al. PEGylated nanomedicines: recent progress and remaining concerns. Expert Opin Drug Deliv 2014, 11, (1):139-54.

  6. Fowler R, Vllasaliu D et al. Uptake and transport of B12-conjugated nanoparticles in airway epithelium. J Control Release 2013, 172:374-381.

  7. Vllasaliu D, et al. Folic acid conjugated chitosan nanoparticles for tumor targeting of therapeutic and imaging agents. Pharm Nanotechnol 2013, 1:184-203.

  8. Fowler R, Vllasaliu D, et al. Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. Small 2013, 9:3282-94.

  9. Moradi E, Vllasaliu D, et al. Ligand density and clustering effects on endocytosis of folate modified nanoparticles. RSC Advances 2012, 2:3025-3033.

  10. Vllasaliu D, et al. Fc-mediated transport of nanoparticles across airway epithelial cell layers. J Control Release 2012, 158, (3):479-486.

  11. Vllasaliu D, et al. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int J Pharm 2010, 400, (1-2):183-193